|Bid||2.60 x 1800|
|Ask||2.85 x 800|
|Day's Range||2.60 - 2.78|
|52 Week Range||2.10 - 4.08|
|Beta (3Y Monthly)||-0.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the Company’s lead asset, MS1819-SD, in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The Company further announced that it plans to initiate the multi-center Phase 2 study that was the subject of the IND in the United States and Europe in the fourth quarter of 2018 and expects it to conclude in 2019.
Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.
NEW YORK, Sept. 24, 2018-- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership with Mayoly ...
The company’s most important announcement year to date has been the completion of the Phase 2a trial for MS1819 in late June. Trial results were favorable and provided evidence of safety and efficacy for the Yarrowia lipolytica-derived lipase in exocrine pancreatic insufficiency (EPI). The company also raised $10 million in a public offering underwritten by Oppenheimer.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be making a company presentation during the Rodman and Renshaw 20th Annual Global Investment Conference in New York at the St. Regis Hotel (Louis XVI B Room) on Wednesday, September 5th at 5:30 p.m. EDT.
AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be making a company presentation at the Cannacord Genuity 38th Annual Growth Conference in Boston, Massachusetts at the InterContinental Boston Hotel (London Room), on Thursday, August 9th at 11:30 a.m. The company’s management will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
AzurRx BioPharma, Inc. (AZRX) announced the completion of the Phase IIa MS1819-SD trial on June 29, 2018 and expects to provide a formal report presenting the data in the fall of 2018 at an as yet unidentified scientific conference. As a reminder, the trial was a Phase 2a open-label, dose escalation study conducted in France, Australia and New Zealand with the goal of identifying the safety of escalating doses and dose response. It was conduted in conjuntion with Mayoly Spindler Laboratories and launched November 17, 2016.
AzurRx BioPharma, Inc. (AZRX) provided an update regarding its Phase 2a trial for MS1819 for treatment of chronic pancreatic insufficiency (EPI) The April 23rd release identified consistent progress in the Phase 2a trial for MS1819 with respect to patient enrollment, safety and dose response. The trial is targeting 12 – 15 patients and is enrolling in France, Australia and New Zealand. Current screening and enrollment trends are on track for a 1H:18 study completion.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
AzurRx BioPharma, Inc. (AZRX) filed their fiscal year 2017 10-K on March 16th providing a financial update on the company’s performance. The filing caps off a year that saw progression of the Phase IIa trial for MS 1819 for treatment of exocrine pancreatic insufficiency (EPI), new patent protection filings and new personnel and board additions. In 2018, the company received approval for a clinical site in France and continued to add new patients.
CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( smm.global ): Research Report Here About AzurRx, Biopharma, ...
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...